covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Controversias en el tratamiento del carcinoma ductal in situ de mama: desenlace ...
Journal Information
Vol. 44. Issue 10.
Pages 443-448 (January 2001)
Share
Share
Download PDF
More article options
Vol. 44. Issue 10.
Pages 443-448 (January 2001)
Full text access
Controversias en el tratamiento del carcinoma ductal in situ de mama: desenlace desafortunado en una paciente de 32 años
Controversies in the treatment of in situ ductal breast carcinoma: unfortunate outcome in a 32-years-old patient
Visits
4552
A. Tubau
Corresponding author
albtunnav@teleline.es

Correspondencia: Hospital de Manacor. Ctra. Manacor-Alcudia, s/n. 07500 Manacor. Mallorca-Balears
, M. Lozano, M. Romero, A. Calvo
Servicio de Obstetricia y Ginecología
A. González del Albaa, I. Matanzab, Ma.I. Galarragac
a Sección de Oncología Médica
b Servicio de Anatomía Patológica
c Servicio de Radiodiagnóstico. Hospital Fundació de Manacor. Mallorca
This item has received
Article information
Resumen

El cáncer de mama es el cáncer más frecuente en la mujer, con una mayor incidencia en los países desarrollados. La mejoría de las técnicas de imagen ha permitido aumentar el diagnóstico de las formas preinvasivas y, con ello, aumentar la posibilidad de aplicar un tratamiento cada vez más conservador

Aunque la detección de formas precoces presupone la obtención de mejores resultados, la evolución de estas pacientes no es siempre según lo esperado, por ello en la bibliografía médica se debaten distintos factores, que puedan ser predictivos, para definir el tratamiento a aplicar. A partir de un caso de evolución desfavorable, repasamos los factores con valor pronóstico que se discuten en la bibliografía actual

Palabras clave:
Cáncer de mama
Carcinoma ductal “in situ” (CDIS)
Tratamiento
Abstract

Breast cancer is the most frequent neoplasia in the females, with a much higher incidence in developed countries. Preinvasive lesions are now diagnosed earlier due to the improvement of imaging techniques, and thus the possibility of conservative treatments is increasing

Early detection of neoplasias usually means better treatment results, but the evolution is often unpredictable, so different prediction factors revise in literature debate in order to define adequate treatments

From a clinical case with unfavorable evolution, we discuss prognostic factors in the literature

keywords:
Breast cancer
Ductal carcinoma in situ (DCIS)
Treatment
Full text is only aviable in PDF
Bibliografía
[1.]
Union Internationale Contre le Cancer, 1997.
Atlas TNM de los tumores, (1998), pp. 123-130
[2.]
V.L. Ernster, J. Barclay, K. Kerlikowske, D. Grady, I.C. Henderson.
Incidence of and treatment for ductal carcinoma in situ of the breast.
Jama, 275 (1996), pp. 913-918
[3.]
M.J. Silverstein, D.N. Poller, J.R. Waisman, W.J. Colburn, A. Barth, E.D. Gierson, et al.
Prognostic classification of breast ductal carcinoma in situ.
Lancet, 345 (1995), pp. 1154-1157
[4.]
E.J. Feuer, L.M. Wun, C.C. Boring.
The lifetime risk of developing breast cancer.
J Nat Cancer Ins, 85 (1993), pp. 892-897
[5.]
Cáncer en España.
Ministerio de Sanidad y Consumo, pp. 141-143
[6.]
L.A. Ries, M.P. Eisner, C.L. Kosary.
SEER Cancer Statistics Review, 1973–1997, National Cancer Institute, (2000),
[7.]
R. Yancik, M. Wesley, L.A. Ries, R. Havlik, B. Edwards, J. Yates.
Effect of Age and Comorbidity in Postmenopausal Breast Cancer Patients Aged 55 Years and Older.
Jama, 285 (2001), pp. 885-892
[8.]
J. Palacios, F. Alameda, M. Conangla, F. González-palacios, A. Suárez.
Anatomía patológica y citología en ginecología oncológica, pp. 131-162
[9.]
P.J. Grases, F. Tresserra, R. Fabregas.
Carcinoma ductal in situ de la mama.
Prog Obstet Ginecol, 42 (1999), pp. 201-215
[10.]
H.M. Shingleton, W.C. Jr. Fowler, J.A. Jordan, W.D. Lawrence.
Oncología ginecológica, pp. 285-297
[11.]
M.J. Silverstein, M. Lagios, S. Groshen, J. Waisman, B. Lewinsky, S. Martino, et al.
The Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the Breast.
N Engl J Med, 340 (1999), pp. 1455-1461
[12.]
R. Holland, J. Hendriks, A. Verbeek, M. Mravunac, J.H. Schuurmans Stekhoven.
Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ.
Lancet, 335 (1990), pp. 519-522
[13.]
S.J. Schnitt, W. Silen, N.L. Sadowsky, J.L. Connolly, J.R. Harris.
Ductal carcinoma in situ (intraductal carcinoma) of the breast.
N Engl J Med, 318 (1988), pp. 898-903
[14.]
N. Bijker, J. Peterse, L. Duchateau, J.P. Julien, I. Fentiman, C.h. Duval, et al.
Risk factors for recurrence and metastasis after breast conserving therapy for CDIS: analysis of European Organitzation for Research and Treatment of Cancer Trials 10853.
J Clin Oncol, 19 (2001), pp. 2263-2271
[15.]
B. Fisher, J. Dignam, N. Wolmark.
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.
J Clin Oncol, 16 (1998), pp. 441-452
[16.]
J.P. Julien, N. Bijker, I. Fentiman, J. Peterse, V. Delledonne, P. Rouanet, et al.
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853.
Lancet, 355 (2000), pp. 528-533
[17.]
H. Moore, R. Foster.
Breast cancer and pregnancy.
Semin Oncol, 27 (2000), pp. 646-653
[18.]
G. Albrektsen, I. Heuch, G. Kvale.
The short-term and long-term effect of a pregnancy on breast cancer risk: a prospective study of 802457 parous norwegian women.
Br J Cancer, 72 (1995), pp. 480-484
[19.]
N.S. Goldstein, F.A. Vicini, L.L. Kestin, M. Thomas.
Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age.
Cancer, 88 (2000), pp. 2553-2560
[20.]
E.R. Fisher, J. Constantino, B. Fisher, A.S. Palekar, C. Redmond, E. Mamounas.
Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17: intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators.
Cancer, 75 (1995), pp. 1310-1319
[21.]
B. Fisher, J. Constantino, D.L. Wickerhamd, C.K. Redmond, M. Kavanah, W.N. Cronin, et al.
Tamoxifen for prevention of breast cancer: report of the National Surgical adjuvant breast and bowel project P-1.
J Natl Cancer Inst, 90 (1998), pp. 1371-1388
[22.]
B. Fisher, J. Dignam, N. Wolmark, D.L. Wickerham, E.R. Fisher, E. Mamounas, et al.
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Lancet, 353 (1999), pp. 1993-2000
[23.]
Documento de consenso de quimioprevención del cáncer de mama.
Sección de prevención del Cáncer Ginecológico de la SEGO, (28 de febrero de 2000),
[24.]
U. Veronesi, P. Maisonneuve, A. Costa, V. Sacchini, C. Maltoni, et al.
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.
Lancet, 352 (1998), pp. 93-97
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos